S2 Table. Dosage modification guideline for irinotecan and 5-FU

ADR	Grade of ADR	Instructions for the dosing of irinotecan and 5-FU
Leukopenia	WBC < 3,000/μL	The dose was temporarily withheld till recovery.
Thrombocytopenia	Platelet ≥ 50,000/ μL, < 100,000/μL	The dose was temporarily withheld till recovery.
	Grade 3 or greater severity	First occurrence: The dose was reduced by one step.[a)] Second occurrence: The dose was reduced by two steps.[b)]
Neutropenia	Grade 2	The dose was reduced by one step without waiting for recovery (the original dose could be given in the next cycle)
	Grade 3 or greater severity	The dose was temporarily withheld till recovery. If the first occurrence persisted for 6 days or longer, the dose was reduced by one step.[a)] If the second occurrence persisted for 6 days or longer, the dose was reduced by two steps.[b)]
Febrile neutropenia	Grade 3 or greater severity	For the first occurrence, the dose was reduced by one step.[a)] For the second occurrence, the dose was reduced by two steps.[b)]
Diarrhea	Grade 3 or greater severity	
Stomatitis	Grade 3 or greater severity	
Myocardial ischemia	Any grade	For irinotecan, no modification was necessary. 5-FU was discontinued.
Hand-foot syndrome	Grade 3 or greater severity	
Other non-hematological toxicities, except alopecia	Grade 2 or greater severity	The dose was temporarily withheld till recovery.

ADR, adverse drug reaction; WBC, white blood cell; 5-FU, 5-fluorouracil. [a)]Irinotecan was reduced to 150 mg/m^2, 5-FU bolus to 320 mg/m^2, and 5-FU infusion to 2,000 mg/m^2, [b)]Irinotecan was reduced to 120 mg/m^2, and 5-FU bolus to 240 mg/m^2, and 5-FU infusion to 1,600 mg/m^2. For irinotecan or 5-FU, after two dose reductions, discontinuation of the drug was recommended. The dose of leucovorin was maintained throughout the treatment period without any dose reduction.